PCH
ZBIO

Polar Capital Holdings’s Zenas BioPharma ZBIO Stock Holding History

Polar Capital Holdings’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.2M Sell
2,412,772
-135,672
-5% -$2.7M 0.14% 109
2026
Q1 		$49.8M Buy
2,548,444
+1,490,835
+141% +$33.5M 0.18% 96
2025
Q4 		$38.4M Buy
+1,057,609
New +$34.8M 0.15% 114

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Polar Capital Holdings's ZBIO Position: Q2 2026 in Review

Polar Capital Holdings reduced its Zenas BioPharma (ZBIO) stake by 5.3% in Q2 2026, selling an estimated $2.7M and leaving 2,412,772 shares worth $61.2M. The position accounts for 0.14% of the portfolio, ranked #109.

Polar Capital Holdings first reported a position in ZBIO in Q4 2025 and has held it in 3 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Polar Capital Holdings held 2,412,772 shares of Zenas BioPharma worth $61.2M as of Q2 2026.
  • Polar Capital Holdings sold 135,672 Zenas BioPharma shares in Q2 2026, an estimated $2.7M.
  • Zenas BioPharma made up 0.14% of Polar Capital Holdings's portfolio in Q2 2026, its #109 holding.
  • Polar Capital Holdings first reported a position in Zenas BioPharma in Q4 2025 and has held it in 3 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.